Breaking News, Collaborations & Alliances

Arcinova, Sterling Pharma Solutions Form Collaboration

Tie-up will enhance the two companies' service offerings to their global client bases



Alnwick, UK-based Arcinova will now have access to Sterling Pharma Solutions’ scale-up and pilot plant assets, which will complement the company’s existing facilities. Sterling Pharma Solutions is headquartered in Cramlington, UK and is just 28 miles from the Arcinova site.

The facilities include pilot plant assets ranging from 50-liter up to 1300-liter capacity, with 5-100kg batch generation capability. The combined service offering will allow Arcinova to ensure technical transfer from grams to 100s kilogram scale and is designed to ensure an integrated facility to meet clients’ drug substance requirements, from preclinical through to full-scale commercial launch phases.

The scale-up process will be executed by trained Arcinova personnel, supported by the infrastructure and capacity of Sterling Pharma Solutions.

Arcinova provides both integrated end-to-end solutions and standalone services to pharmaceutical and biotech companies. It works across drug substance synthesis, drug product manufacture, CMC, bioanalytical and metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent active pharmaceutical ingredients (APIs). It also provides consultancy services and works in partnership with companies throughout the drug development process.

Sterling Pharma Solutions is a provider of small molecule API development and manufacturing services to the global pharmaceutical industry.

“I’m delighted that Arcinova and Sterling Pharma Solutions have forged this partnership,” said Ian Shott, chief executive officer, Arcinova. “By working in collaboration and combining expertise and specialist capabilities, we can offer an even wider ranging service to the global pharmaceutical and biotechnology communities and further strengthen the level of support we offer to our clients.”

Paul Quigley, head of API at Arcinova, said, “This new capability will ensure technical transfer from grams to 100s kilogram scale thanks to our collaboration with Sterling Pharma Solutions. This is a very exciting development for Arcinova and reflects the increased demand we have seen for our API services. In addition, this collaboration demonstrates the strength of North East England’s pharmaceutical sector and our ability to make an impact on a global scale.”

Kevin Cook, chief executive officer, Sterling Pharma Solutions, said, “This collaboration brings together complementary capabilities to make the North East of England the right choice for pharmaceutical development, scale-up and commercial manufacture.”

Launched in 2016, Arcinova operates from a 15,000 square-meter facility on a 34-acre site, which has benefited from decades of investment as a key research and development center for Sanofi and Covance, allowing it to offer a unique range of complementary on-site capabilities as a contract research and development organization (CRDO).

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters